PharmaEngine

PharmaEngine P/TBV

The Price to Tangible Book Value (P/TBV) of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 1.87. In the previous year, Price to Tangible Book Value (P/TBV) was 1.71 — a change of 9.58% (higher).

P/TBV

1.87

YoY

9.58%

Last updated:

Price to Tangible Book Value (P/TBV) of PharmaEngine is 2025 1.87 . Price to Tangible Book Value (P/TBV) of PharmaEngine was 2024 1.71 . It decreases by 9.58% higher compared to the previous year.

The PharmaEngine P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
2.50 TWD
Jan 1, 2019
2.65 TWD
Jan 1, 2020
2.30 TWD
Jan 1, 2021
2.34 TWD
Jan 1, 2022
2.38 TWD
Jan 1, 2023
2.39 TWD
Jan 1, 2024
1.71 TWD
Jan 1, 2025
1.87 TWD
The PharmaEngine P/TBV history
YEARP/TBVYoY
1.87+9.58%
1.71-28.47%
2.39+0.22%
2.38+1.77%
2.34+1.84%
2.30-13.16%
2.65+6.06%
2.50+5.87%
2.36-2.87%
2.43-16.84%
2.92-7.35%
3.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Price to Tangible Book Value (P/TBV) of PharmaEngine is 1.87 in 2025.

Price to Tangible Book Value (P/TBV) of PharmaEngine changed from 1.71 to 1.87, representing a 9.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s PharmaEngine with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — PharmaEngine

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — PharmaEngine